ATE401392T1 - Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion - Google Patents

Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Info

Publication number
ATE401392T1
ATE401392T1 AT05798981T AT05798981T ATE401392T1 AT E401392 T1 ATE401392 T1 AT E401392T1 AT 05798981 T AT05798981 T AT 05798981T AT 05798981 T AT05798981 T AT 05798981T AT E401392 T1 ATE401392 T1 AT E401392T1
Authority
AT
Austria
Prior art keywords
subtype
patients
matched
treatment
inactivated whole
Prior art date
Application number
AT05798981T
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Application granted granted Critical
Publication of ATE401392T1 publication Critical patent/ATE401392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05798981T 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion ATE401392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61572904P 2004-10-04 2004-10-04
US11/243,094 US20060093623A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection

Publications (1)

Publication Number Publication Date
ATE401392T1 true ATE401392T1 (de) 2008-08-15

Family

ID=35695555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05798981T ATE401392T1 (de) 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Country Status (14)

Country Link
US (1) US20060093623A1 (de)
EP (1) EP1797175B1 (de)
JP (1) JP2008515795A (de)
CN (1) CN101056977B (de)
AT (1) ATE401392T1 (de)
AU (1) AU2005290930B2 (de)
BR (1) BRPI0516314A (de)
CA (1) CA2582426A1 (de)
DE (1) DE602005008264D1 (de)
ES (1) ES2310848T3 (de)
IL (1) IL182440A (de)
MX (1) MX2007004028A (de)
RU (1) RU2396346C2 (de)
WO (1) WO2006038124A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213299B1 (de) 2009-01-29 2015-09-09 Michel Vandevelde Impfstoffzusammensetzung auf der Basis eines Virus mit Zinkfingermotiv(en), ihr Herstellungsverfahren und ihre Anwendung
US20100216120A1 (en) * 2009-02-23 2010-08-26 Candace Pert Rapid infectious virus assay
DK2694101T3 (en) * 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
MX2014010482A (es) * 2012-03-02 2015-04-08 Esteve Labor Dr Metodo para la preparacion de vacunas de celulas dendriticas.
EP2821082A1 (de) * 2013-07-05 2015-01-07 Laboratoire Biodim Verfahren zur Herstellung eines inaktivierten Lentivirus, insbesondere HIV, Impfstoff, Kit und Verfahren zur Verwendung
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Seattle Project Corp. HIV antigens and MHC complexes
CA3173793A1 (en) 2020-04-03 2021-10-07 Andrew Ferguson Infectious disease antigens and vaccines
EP4192496A4 (de) 2020-08-06 2025-01-01 Gritstone bio, Inc. Multiepitop-impfstoffkassetten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056838B1 (de) * 1998-02-13 2007-06-20 Adan Rios Verfahren zur entwicklung von einem hiv impfstoff
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
CA2397998A1 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
EP1363662A2 (de) * 2001-02-27 2003-11-26 Institut Pasteur Mhc-1-abhängige präsentation von hiv-1- virionantigenen ohne virale replikation: verwendung zur stimulierung von ctl und impfung in vivo
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane

Also Published As

Publication number Publication date
AU2005290930A1 (en) 2006-04-13
CN101056977A (zh) 2007-10-17
IL182440A (en) 2011-01-31
IL182440A0 (en) 2007-07-24
JP2008515795A (ja) 2008-05-15
BRPI0516314A (pt) 2008-09-02
MX2007004028A (es) 2007-09-11
AU2005290930B2 (en) 2010-12-16
DE602005008264D1 (de) 2008-08-28
RU2007115549A (ru) 2008-11-10
ES2310848T3 (es) 2009-01-16
CN101056977B (zh) 2013-01-30
RU2396346C2 (ru) 2010-08-10
EP1797175A1 (de) 2007-06-20
WO2006038124A1 (en) 2006-04-13
EP1797175B1 (de) 2008-07-16
US20060093623A1 (en) 2006-05-04
CA2582426A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TW200733953A (en) Materials and methods for treating viral infections
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
NZ587798A (en) Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
UA112970C2 (uk) Інактивований вірус вітряної віспи, спосіб його одержання і застосування
RU2008130825A (ru) Применение экстракта бузины
MX2025012624A (es) Oligonucléotidos para usar en la modulacion de respuestas inmunitarias contra la infección viral de la hepatitis b
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
WO2005097618A3 (en) Low dose therapy for treating viral infections
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
WO2021188614A9 (en) Composition, methods of making and using for treating a viral infection, including coronavirus infection
Caruana Old vaccines can fight new pandemics like COVID-19
ZA202402743B (en) Compositions and methods for enhancing and expanding infection induced immunity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties